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ABSTRACT
Background Idiopathic pulmonary fibrosis (IPF) has
a poor prognosis and limited responsiveness to available
treatments. It is characterised by epithelial cell injury,
fibroblast activation and proliferation and extracellular
matrix deposition. Serotonin (5-hydroxytryptamine; 5-HT)
induces fibroblast proliferation via the 5-HTR2A and
5-HTR2B receptors, but its pathophysiological role in IPF
remains unclear. A study was undertaken to determine
the expression of 5-HT receptors in IPF and experimental
lung fibrosis and to investigate the effects of therapeutic
inhibition of 5-HTR2A/B signalling on lung fibrosis in vivo
and in vitro.
Methods and results Quantitative RT-PCR showed that
the expression of 5-HTR1A/B and 5-HTR2B was
significantly increased in the lungs of patients with IPF
(n¼12) and in those with non-specific interstitial
pneumonia (NSIP, n¼6) compared with transplant
donors (n¼12). The expression of 5-HTR2A was
increased specifically in IPF lungs but not in NSIP lungs.
While 5-HTR2A protein largely localised to fibroblasts,
5-HTR2B localised to the epithelium. To assess the
effects of 5HTR2A/B inhibition on fibrogenesis in vivo,
mice were subjected to bleomycin-induced lung fibrosis
and treated with the 5-HTR2A/B antagonist terguride (or
vehicle) in a therapeutic approach (days 14e28 after
bleomycin). Terguride-treated mice had significantly
improved lung function and histology and decreased
collagen content compared with vehicle-treated mice.
Functional in vitro studies showed that terguride is
a potent inhibitor of transforming growth factor b1- or
WNT3a-induced collagen production.
Conclusion The studies revealed an increased
expression of 5-HTR2A specifically in IPF. Blockade of
5-HTR2A/B signalling by terguride reversed lung fibrosis
and is thus a promising therapeutic approach for IPF.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive
and fatal lung disease of unknown origin.1 2 It is
characterised by alveolar epithelial cell damage,
increased deposition of extracellular matrix (ECM)
in the lung interstitium, enhanced fibroblast/
myofibroblast proliferation and activation and,
ultimately, distortion of normal lung architecture
and loss of respiratory function.3 4 The hallmark
lesions of IPF are fibroblast foci, sites featuring
activated myofibroblasts mainly responsible for
altered ECM deposition in the lung interstitium.2
The pathogenesis of IPF includes inappropriate
alveolar regeneration in response to repetitive
epithelial injuries perpetuated by dysregulated
wound repair in response to local inflammation.5 6
While the initial trigger of this disease is most likely
represented by repetitive epithelial injuries of
unknown origin, the interstitial fibroblast/myofi-
broblast represents the key effector cell responsible
for ECM deposition in patients with IPF and in
animal models of lung fibrosis such as the bleo-
mycin-induced mouse model.3 7 8 It is currently
unclear, however, which mediators and pathways
are involved in disease initiation and progression.
While soluble cytokines such as transforming
growth factor (TGF) b1, interleukin (IL)-1b or
WNT ligands have been assigned a pathogenic role
in IPF and experimental models thereof,9e12 thera-
peutic options neutralising their activity have not
been studied in appropriate clinical trials.
Serotonin (5-hydroxytryptamine, 5-HT) exhibits
well-characterised regulatory functions in multiple
physiological systems.13 14 It is involved in the
regulation of cell migration, proliferation, cytokine
production and vasoregulation.15 16 The multiple
actions of 5-HT are mediated by seven different
5-HT receptor subtypes (5-HTR1e5-HTR7).17
Importantly, 5-HT and its receptors 5-HTR2A and
5-HTR2B have been implicated in fibrotic disorders
such as retroperitoneal or pleural fibrosis, carcinoid
heart disease and liver fibrosis.18e20 In addition,
cumulative evidence suggests an important biolog-
ical role for 5-HT signalling in the lung, supported
by increased levels of 5-HT and active signalling
thereof in asthma and pulmonary hypertension.21 22
In addition, recent evidence has suggested that the
5-HTR2A antagonists ketanserin and SB215505
reduced collagen mRNA and protein levels in the
bleomycin-induced mouse model.23 Accordingly,
this evidence demands a detailed characterisation of
5-HT receptor expression in IPF and analysis to
determine whether 5-HT2A/B antagonists represent
a therapeutic option in IPF, particularly since
5-HTR2 antagonists are already in clinical use for
other diseases.24 25 Among these, terguride
(1,1-diethyl-3-(6-methyl-8a-ergolinyl)urea) is
a potent antagonist of 5-HTR2A and HTR2B,
a partial dopaminergic agonist and an a2-adrenolytic
agent.24 26 Terguride is clinically approved, well-
tolerated and has been shown to be efficacious in
the treatment of ovulation disorders due to hyper-
prolactinaemia.27
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The expression and localisation of the 5-HT system in IPF
lungs was investigated and compared with non-specific inter-
stitial pneumonia (NSIP) and donor lungs. We performed
a therapeutic approach in vivo using the mouse model of bleo-
mycin-induced lung fibrosis to determine whether 5-HTR2A/B
antagonism by terguride is a suitable therapeutic option for IPF.
MATERIAL AND METHODS
Human tissue and cells
Lung tissues were obtained from 12 patients with IPF with
a histological pattern of usual interstitial pneumonia (UIP)
(4 women, 8 men; mean6SD age 5769 years), 6 patients with
non-specific interstitial pneumonia (NSIP, fibrotic phenotype)
(4 women, 2 men; mean6SD age 5569 years) and 12 control
subjects (transplant organ donors; 6 women, 6 men; mean6SD
age 40610 years) after explantation. Detailed patient charac-
teristics are shown in table S1 in the online supplement. Human
ATII cells were isolated as previously described.28 The purity and
viability of ATII cell preparations was consistently >90% and
>95%, respectively. Freshly isolated human ATII cells were used
for gene expression analysis.
Animals
Pathogen-free 6e8-week-old female C57BL/6N mice (Charles
River Laboratories, Sulzfeld, Germany) weighing 18e22 g were
used throughout the study. All experiments were performed in
accordance with the guidelines of the ethics committee of
University of Giessen School of Medicine and approved by the
local authorities. Mice had ad libitum access to water and rodent
laboratory chow. Bleomycin sulphate (Laboratories Almirall SA,
Barcelona, Spain) was dissolved in sterile 0.9% saline and applied
as a single dose of 1.5 U/kg body weight in a total volume of
80 ml by orotracheal application. Control mice received 80 ml
saline only. Mice were treated with terguride 14 days after
bleomycin application. As an internal control, a treatment arm
with daily administration of 50 mg/kg imatinib was included in
the study. Treatment with imatinib was started immediately
following instillation of bleomycin. The detailed treatment
scheme is shown in figure S4 in the online supplement.
Immunohistochemistry
Human lungs were submerged in 4% (w/v) paraformaldehyde
after explantation and processed for paraffin embedding.29 30
Immunohistochemical staining of sections (3 mm) was
performed according to the manufacturer ’s protocol (Histostain
Plus Kit; Zymed Laboratories/Invitrogen, Carlsbad, California,
USA). Antigen retrieval was performed in 6.5 mM sodium
citrate pH 6.0 in a pressure cooker, after which endogenous
peroxidase activity was quenched with 3% (v/v) hydrogen
peroxide for 20 min. The following antibodies were used in the
study: 5HTR2A (polyclonal, sc-50396, dilution 1:200; Santa Cruz
Biotechnologies, California, USA); 5HTR2B (polyclonal,
ab12926, dilution 1:200; Abcam, Cambridge, UK). An antibody
against 5HTR2B (polyclonal, HPA012867, dilution 1:100, Sigma-
Aldrich, St Louis, Missouri, USA) was also used and staining was
performed using the Vulcan Fast Red Chromogen Kit (Zymed
Laboratories/Invitrogen). For the negative control, an isotype-
matched non-specific antibody was used (ab2410, dilution 1:200,
Abcam).
Further experimental procedures
The detailed procedures for the determination of terguride levels,
cell culture, quantitative RT-PCR, collagen assay, lung function
and determination of the fibrotic score are provided in the online
supplement.
Statistical analysis
All DCt values obtained from quantitative real-time PCR (qRT-
PCR) were analysed for normal distribution with the Shapiro-
Wilk test using assignment of a normal distribution with
p>0.05 and confirmed using quantile-quantile plots. The means
of indicated groups were compared using the two-tailed Student
t test or one-way analysis of variance (ANOVA) with Tukey
HSD post hoc test for studies with more than two groups. The
results were considered statistically significant when p<0.05.
RESULTS
Expression analysis of 5-HT receptors and the 5-HT transporter
5-HTT in donor and IPF lung specimens
Initially we analysed the expression of 5-HT receptors and the
5-HT transporter 5-HTT in lung tissue samples from controls
(transplant donors) and from patients with NSIP or IPF using
qRT-PCR. As shown in figure 1, all investigated 5-HT receptors
except 5-HTR2C were expressed in normal as well as diseased
lung tissue. 5-HTR1A, 5-HTR1B (figure 1A), 5-HTR2A and
5-HTR2B (figure 1B) were markedly upregulated in IPF lungs
(mean6SEM log-fold change 2.3660.43, 2.1460.46, 3.7460.41
and 1.6060.32, respectively). 5-HTTwas expressed at high levels
in control lungs; it was dramatically downregulated in IPF (log-
fold change 4.0560.71, figure 1C) but not in NSIP lungs
(fibrotic NSIP). Interestingly, in NSIP lung specimens 5-HTR2A
and 5-HTT were not differentially regulated compared with
control subjects but 5-HTR1A, 5-HTR1B and 5-HTR2B were also
upregulated (figure 1). The increased expression of 5-HTR2A thus
presented a specific event in UIP.
Localisation of 5-HTR2A and 5-HTR2B in donor and IPF lung
specimens
Following the initial results, we focused our study on protein
localisation of 5-HTR2A and 5-HTR2B. In order to localise cell
types capable of 5-HT signalling via these 5-HTR, we assessed
the distribution of 5-HTR2A and 5-HTR2B in donor and IPF lung
tissue sections by immunohistochemistry (figures 2 and 3,
respectively). 5-HTR2A was mainly expressed in bronchial and
vascular smooth muscle cells; in IPF, additional staining in
interstitial fibroblasts was observed (figure 2, arrows). As shown
in figure 3 and figure S2 in the online supplement, 5-HTR2B was
expressed largely in endothelial cells in control tissue. In IPF
lungs, 5-HTR2B staining was mainly observed in bronchial and
alveolar epithelial cells (figure 3A, arrowheads). To further
corroborate these results we quantified the cell-specific gene
expression patterns of 5-HTR2A and 5-HTR2B in primary human
ATII cells derived from patients with IPF or transplant donors
using qRT-PCR. As shown in figure 3B, there was a significant
increase in 5-HTR2B mRNA expression in IPF ATII cells whereas
the 5-HTR2A level was not significantly different in human ATII
cells from patients with IPF and transplant donors.
Administration of the 5-HTR2A/B antagonist terguride in vivo
We next assessed whether inhibition of 5-HTR2A/B represented
an effective therapeutic option in lung fibrosis using mice
subjected to orotracheal instillation of bleomycin, a well-
accepted experimental model of lung fibrosis.31 First we analysed
the expression of 5-HT receptors and 5-HTT in experimental
lung fibrosis. As shown in figure S1 in the online supplement,
5-HTR2A and 5-HTR2B were significantly upregulated 7 and
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14 days after bleomycin injury, which is in agreement with
previous reports.23
Next we administered the clinically approved 5-HTR2A/B
antagonist terguride to mice subjected to bleomycin. In order to
ensure that terguride partitions into lung tissue, we next
determined the concentrations of terguride in plasma and lung
tissue under our experimental conditions (see figure S3 in online
supplement). One hour after intraperitoneal administration of
1.2 mg/kg terguride the plasma concentrations of terguride
ranged from 2.06e20.26 nM. In perfused lung tissue, comparable
terguride concentrations to plasma were detected in all animals
independent of the degree of fibrosis (figure S3 in online
supplement). This indicated that terguride rapidly equilibrated
in lung tissues and during the time course of bleomycin-induced
lung fibrosis. Treatment with terguride was well tolerated and
no side effects were observed throughout the study. The body
weights of the mice were not significantly different between
bleomycin-treated mice, independent of treatment with vehicle
or terguride (see figure S3 in online supplement).
Effects of 5-HTR2A/B antagonism on lung fibrosis in vivo
To determine whether 5-HTR2A/B antagonism affected the
progression of lung fibrosis we initiated treatment with
terguride 14 days after bleomycin instillation (referred to as
‘therapeutic approach’). Mice were treated with two different
doses of terguride by intraperitoneal application twice daily
until day 28. As an internal control, a treatment arm with daily
administration of 50 mg/kg imatinib was included in the
study.32 Treatment with imatinib was started immediately after
instillation of bleomycin (referred as ‘preventive approach’). The
detailed treatment scheme is shown in figure S4 in the online
supplement. We investigated the effects of 5-HTR2A/B
Figure 2 Expression and localisation of the serotonin (5-HT) receptor 5-HTR2A in lung tissue from controls (transplant donors) and patients with
idiopathic pulmonary fibrosis (IPF). Immunohistochemical staining was performed on tissue sections of donor lungs (left panels) and IPF lungs (right
panels). Stainings are representative of four independent experiments using at least three different donor or IPF lung tissues. Scale bars indicate
100 mm. Arrows indicate positive staining of fibroblasts in IPF.
7-
6-
5-
4-
3-
2-
1-
0
-13
-11
-9
-7
-5
-3
-1
1
3
6-
4-
2-
0
2
4
re
la
tiv
e 
m
R
N
A
 le
ve
l (Δ
C
t)
A
RTH-5 A1 RTH-5 B1
*
* C
re
la
tiv
e 
m
R
N
A
 le
ve
l (
ΔC
t)
TTH-5
*
B
re
la
tiv
e 
m
R
N
A
 le
ve
l (
ΔC
t)
RTH-5 A2 RTH-5 B2
∗ *
*
21=n ronoD
21=n FPI
6=n PISN
Figure 1 mRNA expression profile of serotonin (5-HT) receptors (A) 5-HTR1A,1B, (B) 5-HTR2A,2B and (C) the 5-HT transporter (5-HTT) in lung samples
from controls (transplant donors) and patients with non-specific interstitial pneumonia (NSIP) and idiopathic pulmonary fibrosis/usual interstitial
pneumonia (IPF/UIP) assessed by quantitative real-time PCR. The results are derived from 12 controls, 6 patients with NSIP and patients with 12
IPF/UIP and are presented as single values per lung sample. *p<0.05.
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antagonism by terguride in vivo on key features of lung fibrosis
such as impaired respiratory function, destroyed lung architec-
ture and increased collagen deposition.
The assessment of lung compliance in vivo showed slight but
significant improvements in lung function of terguride-treated
but not imatinib-treated mice (figure 4A). We next assessed the
degree of lung fibrosis by determination of the total hydroxy-
proline content (figure 4B) and fibrotic score (figure 4C). As
shown in figure 4B, mice subjected to 5-HTR2A/B antagonism by
terguride had significantly less total collagen than vehicle-
treated controls (bleomycin+vehicle: 148622%, bleomycin
+terguride 0.4: 122627%, bleomycin+terguride 1.2: 91621%,
n¼10 each). These findings were corroborated by the fact that
5-HTR2A/B antagonism also led to a dose-dependent decrease in
the fibrotic score (bleomycin+vehicle: 3.160.3, bleomycin
+terguride 0.4: 1.960.6, bleomycin+terguride 1.2: 1.4660.2
compared with saline-treated controls, n¼10 each; figure 4C).
The effects of terguride on collagen content as well as the
fibrotic score were comparable to those of imatinib treatment
(preventive approach). Finally, immunohistochemistry of
vehicle- and terguride-treated mouse lungs confirmed a marked
attenuation of fibrosis with less ECM deposition and restored
lung architecture (figure 4D).
Effects of 5-HTR2A/B antagonism on lung fibrosis in vitro
Fibroblasts are the key effector cells in lung fibrosis and are
responsible for enhanced ECM deposition. We therefore assessed
the effects of terguride on lung fibroblasts stimulated by the
profibrotic mediators transforming growth factor (TGF)-b1 or
WNT3a. Both, TGF-b1 and WNT3a treatment of human lung
fibroblasts (HFL-1) led to a significant induction of the ECM
components type I collagen a1 (Col1a1) as assessed by qRT-PCR
(figure 5A). Moreover, these changes were confirmed at the total
collagen level as assessed by Sircol assay (figure 5B). Most
importantly, terguride treatment resulted in a significant
decrease in TGF-b1-induced as well as WNT3a-induced collagen
production at the mRNA (TGF-b1: 2.6160.65, TGF-
b1+terguride 1000: 0.2660.77, WNT3a: 3.9960.55, WNT3a
+terguride 1000: 0.3960.22; figure 5A) and protein level (TGF-
b1: 1.3460.29, TGF-b1+terguride 1000: 0.7160.28, WNT3a:
1.2860.16, WNT3a+terguride 1000: 0.9660.12, figure 5B).
DISCUSSION
In this study we found altered expression of 5-HTR in IPF,
suggesting that 5-HT signalling is altered in IPF. We analysed
lung tissue samples from patients with IPF, NSIP and controls
(transplant donors) and observed a marked upregulation of
Figure 3 Expression and localisation of the serotonin (5-HT) receptor 5-HTR2B in lung tissue from controls (transplant donors) and patients with
idiopathic pulmonary fibrosis (IPF). (A) Immunohistochemical stainings are representative of four independent experiments using at least three different
donor or IPF lung tissues and two different primary antibodies. Scale bars indicate 100 mm. Arrows indicate positive staining of fibroblast in IPF,
arrowheads highlight staining in bronchial and alveolar epithelial cells. (B) The mRNA levels of 5-HTR2A and 5-HTR2B were determined by qRT-PCR in
primary human ATII cells (n¼4) isolated from IPF lung tissue and compared with ATII cells from donor lungs. The results are plotted as fold change
(2DDCt) of mRNA levels in IPF-derived vs donor-derived cells and presented as mean6SEM, *p<0.05.
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5-HTR1A/B and 5-HTR2A/B but a dramatic downregulation of
5-HTT in IPF. Interestingly, in NSIP lung specimens 5-HTR2A
was not differentially regulated compared with control subjects,
which suggests this is a specific event in UIP.
We demonstrated that inhibition of 5-HTR2A and 5-HTR2B
resulted in marked attenuation of bleomycin-induced lung
fibrosis and thereby may be a suitable therapeutic approach in
lung fibrosis. These findings are of special interest as IPF has
a poor prognosis owing to limited responsiveness to currently
available therapies.
5-HT and its receptors 5-HTR2A and 5-HTR2B have been
implicated in fibrotic disorders such as retroperitoneal fibrosis,
nephropathies, carcinoid heart disease and liver fibrosis.18e20
Cumulative evidence of the biological role of 5-HT in the lung has
emerged, such as controlling vasoreactivity or broncho-
reactivity.33 Under disease conditions such as asthma, increased
levels of 5-HT correlate with the clinical status and pulmonary
function,34 and several studies have indicated of the involvement
of 5-HT in the aetiology of primary pulmonary hypertension.35 36
5-HT leads to vasoconstriction and vascular proliferation under
hypoxic conditions,35 and enhanced 5-HTR2B expression seems to
be centrally involved in the development of this disease.36
We quantified the mRNA expression levels of distinct 5-HT
receptors and of 5-HTT in IPF, NSIPand control lung tissues. High
levels of 5-HTR2A and 5-HTR2B were observed in the lung but
5-HTR2C was not detected. The expression of 5-HTR2A and
5-HTR2B was highly upregulated in IPF lung tissue and localised
to key cell types involved in disease pathogenesis such as
epithelial cells and fibroblasts. This is in line with previous find-
ings that 5-HTR2A and 5-HTR2B are expressed in the human
lung37 as well as in lung epithelial cell lines and fibroblasts.33 38
Most importantly, increased expression of 5-HTR2A was specific
for IPF as no regulation of 5-HTR2Awas observed in NSIP. In the
NSIP lung specimen, classified as fibrotic NSIP, the highest
expression level for 5-HTR1A and 5-HTR1B was observed. NSIP
can be divided into ‘cellular ’/‘non-fibrotic’ and ‘fibrotic’ pheno-
types. In non-fibrotic NSIP mainly inflammatory cells are found
whereas, in fibrotic NSIP, areas of thickened fibrotic septa with
fewer inflammatory cells are predominant. Importantly, non-
fibrotic NSIP has a significantly better prognosis and survival rate
than fibrotic NSIP.39 40 Given the results of this study, future
experiments may focus on 5-HTR1A and 5-HTR1B expression in
non-fibrotic NSIP lung tissue specimens to elucidate whether this
would be useful to distinguish subtypes of NSIP.
High levels of 5-HTT were found in the normal lung, with
a dramatic downregulation in IPF. Decreased 5-HTT expression
was also observed in bleomycin-induced lung fibrosis. 5-HTT is
a key protein limiting systemic availability of 5-HT and is
responsible for 5-HT uptake and subsequent inactivation of the
amine passing through the lung. Mekontso-Dessap et al reported
that mice deficient in 5-HTT develop cardiac fibrosis and
valvulopathy, providing evidence for an inverse relationship
Figure 4 Lung function and collagen
content after terguride treatment in
experimental lung fibrosis. Mice were
subjected to saline or bleomycin
instillation and treated with terguride
(ter). (A) Lung compliance
measurements were obtained on days
14, 21 and 28. After 28 days the lungs
were processed for (B) hydroxyproline
measurement, (C) determination of the
fibrotic score in lung sections stained
with haematoxylin and eosin or
(D) histological assessment using
haematoxylin and eosin staining of lung
sections. Scale bars indicate 50 mm.
Figure 5 Effect of terguride (ter)
treatment on transforming growth factor
(TGF)-b1- induced or WNT3a-induced
type I collagen a1 expression in
fibroblasts. (A) Using qRT-PCR analysis,
the mRNA level of type I collagen a1
was assessed in human lung fibroblasts
after stimulation with TGF-b1 (2 ng/ml)
or WNT3a (100 ng/ml) for 12 h as
indicated (n¼4). (B) Human lung
fibroblasts were stimulated with TGF-b1
(2 ng/ml) or WNT3a (100 ng/ml) for
24 h and the total collagen content was
measured using the Sircol collagen assay (n¼4).
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between 5-HTT and fibrogenesis.41 Ablation of 5-HTT reduces
the levels of 5-HT because platelet 5-HT is known to contribute
99% of 5-HT in the blood. Since 5-HTT is also the predominant
pathway of 5-HTclearance by lung cells, an increase in the local
5-HT concentration in the lung with concomitant increases in
binding to and signalling through 5-HT2 receptors may be the
consequence.41 Downregulation of 5-HTT and upregulation of
5-HTR2A and 5-HTR2B may lead to increased 5-HT levels and
enhanced receptor availability, respectively, and thus synergistic
regulation of fibrogenesis. A detailed investigation of the
underlying mechanisms remains elusive owing to limitations of
investigative tools. In particular, the assessment of free and
unbound 5-HT in nanomolar concentrations in blood is influ-
enced by artificial activation of platelets and is therefore difficult
to assess and interpret in mouse models.
We assessed the potential antifibrotic effects of 5-HTR2A/B
antagonism using a therapeutic approach in the mouse model of
bleomycin-induced lung fibrosis. We administered terguride,
which is clinically approved for the treatment of ovulation
disorders due to hyperprolactinaemia and hyperprolactaemic
pituitary adenoma.27 Terguride belongs to the ergoline class of
compounds which have been shown to have a high affinity to
several 5-HT receptor isoforms. In contrast to most ergoline
derivatives including ergotamine, pergoline, cabergoline and
bromocriptine, terguride is a potent 5HTR2A and 5HTR2B
receptor antagonist.24 Chronic treatment with ergoline deriva-
tives such as pergolide and, to a lesser extent, cabergoline or with
anorexic drugs such as fenfluramine has been associated with
retroperitoneal, pleural and pericardial fibrosis as well as valvular
heart disease.42 43 These drugs exhibit 5-HTR2B receptor agonist
properties. In contrast, terguride acts as a non-surmountable
antagonist on 5-HTR2B. Interestingly, Hauso et al recently
showed that terguride treatment prevented 5-HT-induced heart
valve disease and hypertrophy in rats.44
We have shown that administration of terguride at two
different doses in a therapeutic approach had potent dose-
dependent therapeutic effects in the mouse model of bleomycin-
induced lung fibrosis. This model has been widely used for drug
efficiency studies over the years, but most compounds have been
tested in a preventive rather than a therapeutic approach. The
preventive approach interferes mostly with the inflammatory
and early fibrogenic response whereas the therapeutic approach
acts on the progression of fibrosis, better reflecting the clinical
situation in IPF.31 We showed that treatment with terguride in
a therapeutic fashion led to a significant improvement in respi-
ratory function, collagen deposition, lung architecture and
survival. This suggests that terguride may have anti-remodelling
properties. Previous evidence has indicated that 5-HT binding to
5-HTR2A exerts mitogenic properties via enhanced TGF-b1
expression. This mechanism seems to be regulated via protein
kinase C and extracellular signal-regulated kinase.19 In addition,
5-HTR2B has been reported to interact with the platelet-derived
growth factor receptor pathway to regulate cell cycle progres-
sion.45 Both receptors may provide possible pathways which lead
to the reverse actions of 5-HTR2A/B antagonism by terguride. We
have further corroborated the interaction between 5-HTR and
TGF-b1 signalling, demonstrating that 5-HTR is involved
in collagen production in human lung fibroblasts induced by
TGF-b1.
Our findings are further validated by a recent study addressing
the role of 5-HT signalling in experimental lung fibrosis. Fabre
et al23 reported increased lung 5-HT levels and 5-HTR2A and
5-HTR2B expression during fibrogenesis in the bleomycin model
of lung fibrosis, which we have confirmed in this study. Using
a preventive approach and generic 5-HTR2A/B antagonists in the
bleomycin model, they also demonstrated attenuation of lung
fibrosis with the inhibitors ketanserin (a 5-HTR2A inhibitor) and
SB215505 (a 5-HTR2B inhibitor).23 Our results are consistent
with these findings, thus confirming the relevance of 5-HT
signalling in lung fibrosis and its role as a therapeutic target. In
addition, we have advanced the understanding of the role of
5-HT in the pathophysiology of IPF by (1) characterising and
quantifying in detail the expression of 5-HT receptors in human
IPF/UIP, NISP and control tissues; (2) demonstrating the thera-
peutic feasibility of terguride in the experimental model of lung
fibrosis using therapeutically relevant conditions, thereby
providing a rationale for translational research of a well-char-
acterised and safe drug in pulmonary fibrosis; and (3) by inves-
tigating in detail the biological mechanisms involved in the
therapeutic effect of terguridedfor example, by demonstrating
a significant role of 5-HTR2A/B in collagen turnover induced by
the profibrotic mediators TGF-b1 and WNT3a.
In summary, we present strong evidence for an important role
of 5-HT signalling via 5-HTR2A/B in lung fibrosis in vivo and in
vitro, and the possibility of selectively and safely modulating
this pathway in vivo which may provide a possible therapeutic
approach for patients with IPF.
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